A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy

被引：0

作者：

Nath, Karthik ^{[1
]}

Shekarkhand, Tala ^{[2
]}

Salcedo, Meghan ^{[2
]}

Derkach, Andriy ^{[3
]}

Rueda, Siobhan ^{[4
]}

Chansakul, Aisara ^{[5
]}

Hulcrantz, Malin ^{[2
]}

Korde, Neha ^{[2
]}

Shah, Urvi A. ^{[2
]}

Tan, Carlyn ^{[2
]}

Chung, David J. ^{[1
,6
]}

Lahoud, Oscar B. ^{[6
]}

Hassoun, Hani ^{[2
]}

Lesokhin, Alexander M. ^{[1
,2
]}

Landau, Heather J. ^{[6
]}

Shah, Gunjan ^{[1
,6
]}

Scordo, Michael ^{[1
,6
]}

Giralt, Sergio A. ^{[1
,6
]}

Usmani, Saad Z. ^{[1
,2
]}

Roshal, Mikhail ^{[7
]}

Landgren, Ola ^{[8
]}

Mailankody, Sham ^{[1
,2
,9
,10
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Cellular Therapy Serv, New York, NY USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, New York, NY USA

[3] Mem Sloan Kettering Canc Ctr, Dept Biostat & Epidmiol, New York, NY USA

[4] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA

[5] Weill Cornell Med Coll, Emergency Dept, Div Emergency Med, New York, NY USA

[6] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, New York, NY USA

[7] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY USA

[8] Univ Miami, Sylvester Comprehens Canc Ctr, Myeloma Program, Miami, FL USA

[9] Mem Sloan Kettering Canc Ctr, Myeloma Serv, 1275 York Ave, New York, NY 10065 USA

[10] Mem Sloan Kettering Canc Ctr, Cellular Therapeut Serv, 1275 York Ave, New York, NY 10065 USA

来源：

LEUKEMIA & LYMPHOMA | 2022年 / 63卷 / 14期

关键词：

OUTCOMES;

D O I：

10.1080/10428194.2022.2131417

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3488 / 3492

页数：5

共 50 条

[1] The Prognostic Significance of Minimal Residual Disease Detection after Induction and ASCT to the Patients with Multiple Myeloma
Yao, Weiqin
Zhu Mingqing
Yao Feirong
Yan, Lingzhi
Jin, Song
Shang, Jingjing
Yao, Ying
Yan, Shuang
Wu, Depei
Fu, ChengCheng
BLOOD, 2018, 132
[2] Genetically Undetectable and Negative Minimal Residual Disease after Induction Therapy Are Equally Crucial for Survival in Multiple Myeloma
Cui, Jian
Liu, Jiahui
Fan, Huishou
Qiu, Lugui
Anderson, Kenneth C.
An, Gang
BLOOD, 2022, 140 : 7185 - 7186
[3] Genetically undetectable and negative minimal residual disease after induction therapy are equally important for survival in multiple myeloma
Cui, Jian
Liu, Jiahui
Fan, Huishou
Yan, Wenqiang
Xu, Jingyu
Du, Chenxing
Deng, Shuhui
Qiu, Lugui
An, Gang
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S59 - S60
[4] Low Intensity Daratumumab to Treat Rersistent/Recurrent Minimal Residual Disease in Multiple Myeloma
Yan, Lingzhi
Shi, Xiaolan
Wang, Jing
Jin, Song
Yao, Ying
Wang, Panfeng
Shang, Jingjing
Zhai, Yingying
Yan, Shuang
Xu, Yun
Meng, Jiajia
Yao, Weiqin
Ma, Xiao
Fu, Chengcheng
Wu, Depei
BLOOD, 2024, 144 : 4750 - 4751
[5] MAINTENANCE THERAPY WITH BORTEZOMIB IN PATIENTS WITH MULTIPLE MYELOMA (MM) AFTER ASCT AND MINIMAL RESIDUAL DISEASE (MRD)
Solovev, M.
Mendeleeva, L.
Pokrovskaya, O.
Gemdzhian, E.
Galtseva, I.
Davydova, J.
Firsova, M.
Nareyko, M.
Abramova, T.
Savchenko, V.
HAEMATOLOGICA, 2017, 102 : 531 - 531
[6] Minimal residual disease diagnostics in patients with multiple myeloma
Huhn, S.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 128 - 128
[7] Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma
Costa, Luciano J.
Chhabra, Saurabh
Medvedova, Eva
Dholaria, Bhagirathbhai R.
Schmidt, Timothy M.
Godby, Kelly N.
Silbermann, Rebecca
Dhaka, Binod
Bal, Susan
Gid, Smith
D'Souza, Anita
Hall, Aric
Hardwick, Pamela
Omel, James
Cornell, Robert F.
Had, Parameswaran
Callander, Natalie S.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (25) : 2901 - +
[8] MINIMAL RESIDUAL DISEASE AFTER BMT FOR MULTIPLE-MYELOMA
BIRD, JM
SAMSON, D
RUSSELL, NH
BLOOD, 1993, 82 (10) : A199 - A199
[9] Minimal Residual Disease in Multiple Myeloma
Munshi, Nikhil C.
Anderson, Kenneth C.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (20) : 2523 - 2526
[10] Minimal residual disease for multiple myeloma
Avet-Loiseau, Herve
Corre, Jill
HEMATOLOGIE, 2019, 25 : 36 - 39

← 1 2 3 4 5 →